Displaying drugs 26 - 50 of 59 in total
Phenacemide
Phenacemide is used to control certain seizures in the treatment of epilepsy. This medicine acts on the central nervous system (CNS) to reduce the number and severity of seizures.
Approved
Matched Description: … Phenacemide is used to control certain seizures in the treatment of epilepsy. …
Diazepam
A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of gamma-aminobutyric acid activity. It is used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and...
Approved
Illicit
Investigational
Vet approved
Matched Description: … development is subsequently an important addition to the rescue therapy tool chest for patients with epilepsy …
Trimethadione
An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378)
Approved
Felbamate
Felbamate is an anticonvulsant drug used in the treatment of epilepsy. In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization). Alternatively, it is used to treat partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak...
Approved
Matched Description: … Felbamate is an anticonvulsant drug used in the treatment of epilepsy. …
Zonisamide
Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of...
Approved
Investigational
Oxcarbazepine
Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of carbamazepine and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exists as a racemate...
Approved
Carbamazepine
Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1....
Approved
Investigational
Cannabidiol
Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact...
Approved
Investigational
Matched Description: … - Lennox-Gastaut syndrome and Dravet syndrome, which are among the two most difficult types of epilepsy ... significantly with regards to its usefulness in a number of medical conditions ranging from anxiety to epilepsy ... recommended approval of Epidiolex (cannabidiol oral solution) for the treatment of two rare forms of epilepsy …
Tramadol
Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to codeine and morphine. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered...
Approved
Investigational
Seletracetam
Seletracetam is a pyrrolidone derivative and with a structural similarity to newer generation antiepileptic drug levetiracetam. It binds to the same target as levetiracetam but with higher affinity and has shown potent seizure suppression in models of acquired and genetic epilepsy with high CNS tolerability. It is predicted to have...
Investigational
Matched Description: … Food and Drug Administration (FDA) investigated as treatment of epilepsy and partial epilepsy however ... but with higher affinity and has shown potent seizure suppression in models of acquired and genetic epilepsy …
Vinpocetine
Vinpocetine has been investigated for the treatment of Epilepsy.
Investigational
Matched Description: … Vinpocetine has been investigated for the treatment of Epilepsy. …
Muscimol
Muscimol has been used in trials studying the treatment of Epilepsy and Parkinson's Disease.
Investigational
Matched Description: … Muscimol has been used in trials studying the treatment of Epilepsy and Parkinson's Disease. …
Talampanel
Talampanel is a substance that is being studied in the treatment of brain tumors and other brain disorders, such as epilepsy and Parkinson disease. It is a type of AMPA receptor antagonist.
Investigational
Matched Description: … substance that is being studied in the treatment of brain tumors and other brain disorders, such as epilepsy …
LIC-477
LIC-477is indicated to be suitable for the treatment of psychosomatic disturbances, epilepsy, trigeminal neuralgia and cerebral spasticity.
Investigational
Matched Description: … LIC-477is indicated to be suitable for the treatment of psychosomatic disturbances, epilepsy, trigeminal …
ICA-105665
ICA-105665 is a novel small molecule compound for the treatment of epilepsy. It is a novel opener of the KCNQ ion channel which in preclinical studies has demonstrated a broad spectrum of activity in models of epilepsy. In addition, ICA-105665 has also demonstrated activity in certain models of neuropathic pain.
Investigational
Matched Description: … ICA-105665 is a novel small molecule compound for the treatment of epilepsy. ... ion channel which in preclinical studies has demonstrated a broad spectrum of activity in models of epilepsy …
Valrocemide
Investigational
Progabide
Progabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors. In clinical trials, progabide has been investigated for Parkinson's disease, schizophrenia, clinical depression and anxiety disorder; its therapeutic effectiveness in these...
Experimental
Matched Description: … It is commonly used in the treatment of epilepsy. …
Apinocaltamide
Apinocaltamide is under investigation in clinical trial NCT03239691 (A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients).
Investigational
Matched Description: … investigation in clinical trial NCT03239691 (A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy …
Padsevonil
Padsevonil is under investigation in clinical trial NCT03695094 (A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil).
Investigational
Matched Description: … Padsevonil is under investigation in clinical trial NCT03695094 (A Study in Participants With Epilepsy …
Remacemide
Investigational
Metharbital
Metharbital is a barbiturate anticonvulsant, similar to phenobarbital, marketed as Gemonil by Abbott Laboratories. It was patented in 1905 by Emil Fischer of Merck.
Withdrawn
JNJ-26489112
JNJ-26489112 is under investigation in clinical trial NCT00579384 (A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy).
Investigational
Matched Description: … on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy …
DP-VPA
DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure frequency.
Investigational
Matched Description: … version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy …
Barbexaclone
Barbexaclone, a salt compound of propylhexedrine and phenobarbital, is a potent antiepileptic. By weight, barbexaclone is 40% propylhexedrine and 60% phenobarbital. While barbexaclone has sedative properties, propylhexedrine has psychostimulant properties intended to offset these sedative effects. Pharmacokinetic studies have demonstrated that the pharmacokinetics of phenobarbital given as barbexaclone are not...
Experimental
Displaying drugs 26 - 50 of 59 in total